Pfizer increases Indian subsidiary investment

13 April 2009

Global drug giant Pfizer has made an offer of 675.00 rupees per share, or 6.8 billion ($137.7 million) rupees in total, to increase the stake  in its indirect Indian subsidiary to 75% from the current level of 41%.  Shares in the division rose 9% to 677 rupees in morning trading on the  day of the news, April 13.

To adhere to Indian law, Pfizer will make a public announcement of the  deal before it makes the offer for the additional 34% of its subsidiary  through the Bombay Stock Exchange and the National Stock Exchange of  India. The action will open in June.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK



Company News Directory



Companies featured in this story

More ones to watch >






Company Spotlight